Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
